Tyson Foods Q1 earnings beat estimates as chicken demand offsets beef weakness
proactiveinvestors.com
Want to monitor VOR?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor VORVor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.